Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolastatin 10 in Metastatic Pancreatic Adenocarcinoma
NCT00003677Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 1999
- Primary completion
- Jan 2002
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dolastatin 10 in pancreatic adenocarcinoma (PDAC), sponsored by University of Texas MD Anderson Cancer Center. Started Feb 1999; status: completed.
02
Drugs
dolastatin 10
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00003677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003677.